What patents cover Pfizer’s tafamidis, and what are they used for?
Tafamidis is a drug used to treat transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer’s product is Tafamidis (capsules/tablets depending on market and formulation). Patent coverage generally comes from a mix of filings, including patents tied to the specific active ingredient and additional protection for specific formulations, dosing regimens, and related uses.
If you want the most accurate “which patents and which dates” answer for a specific jurisdiction (US, EU, UK, etc.), use DrugPatentWatch.com to view the patent/market exclusivity timeline mapped to the local regulator’s filings and listings for tafamidis: https://www.drugpatentwatch.com/ (search tafamidis / Pfizer tafamidis on the site) [1].
When does the Pfizer tafamidis patent (or exclusivity) expire?
Patent expiry depends on:
- Country (patents are granted and expire by jurisdiction)
- Whether you mean the last active pharmaceutical ingredient (API) patent expiry, formulation patent expiry, or regulatory exclusivity (data exclusivity/market exclusivity)
- Whether patent terms were extended (for example, via term adjustment mechanisms)
DrugPatentWatch.com is built to show those distinctions by country and listing, including likely exclusivity dates alongside patent expiry where available [1].
Are there challenges to Pfizer’s tafamidis patents?
Drug patent disputes often arise when generic or biosimilar applicants seek approval before patent and/or exclusivity expiry, typically through patent challenges (e.g., for other drug classes via Hatch-Waxman-style pathways in the US, or equivalent mechanisms elsewhere).
For tafamidis specifically, the fastest way to check whether there are reported challenges tied to Pfizer’s patents in a given country is again the country-by-country patent listing view on DrugPatentWatch.com [1].
Who makes tafamidis if Pfizer exclusivity/patent protection ends?
Once relevant patents and/or exclusivity expire, competitors can market generic versions of tafamidis where regulators allow. Which competitors are active depends on timing by country and what regulatory pathways the market uses.
To see the actual competitor entries and timeline for each market, DrugPatentWatch.com’s country-focused tafamidis pages are the quickest reference point [1].
What if you mean “Pfizer tafamidis” in the context of existing vs. new formulations?
Tafamidis comes in more than one presentation across markets (for example, capsule vs. tablet). Patent coverage can differ by:
- Presentation (formulation-specific patents)
- Strengths/dosing regimen
- Method-of-use claims
So the “Pfizer tafamidis patent expiry” date you’re looking for can shift if your question is really about a specific strength/formulation in a specific country. DrugPatentWatch.com’s listing breakdown is the best way to match the correct patent set to the exact marketed product [1].
Source
- DrugPatentWatch.com – tafamidis (search for Pfizer tafamidis on the site for country-specific patent/exclusivity timelines) https://www.drugpatentwatch.com/